About Recursion Pharmaceuticals, Inc.
https://www.recursion.comRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
CEO
Christopher C. Gibson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 151
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:39.78M
Value:$192.93M
ARK INVESTMENT MANAGEMENT LLC
Shares:33.55M
Value:$162.7M
BLACKROCK, INC.
Shares:31.74M
Value:$153.94M
Summary
Showing Top 3 of 348
About Recursion Pharmaceuticals, Inc.
https://www.recursion.comRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.17M ▼ | $147.78M ▼ | $-162.25M ▲ | -3.14K% ▼ | $-0.36 ▲ | $-141.21M ▲ |
| Q2-2025 | $19.1M ▲ | $175.17M ▼ | $-171.9M ▲ | -899.84% ▲ | $-0.41 ▲ | $-147.57M ▲ |
| Q1-2025 | $14.74M ▲ | $184.28M ▲ | $-202.49M ▼ | -1.37K% ▲ | $-0.5 ▲ | $-182.81M ▼ |
| Q4-2024 | $4.51M ▼ | $175.49M ▲ | $-178.91M ▼ | -3.97K% ▼ | $-0.53 ▼ | $-165.34M ▼ |
| Q3-2024 | $26.08M | $112.36M | $-95.67M | -366.82% | $-0.34 | $-87.92M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $659.84M ▲ | $1.4B ▲ | $352.58M ▼ | $1.05B ▲ |
| Q2-2025 | $528.22M ▲ | $1.3B ▼ | $383.21M ▲ | $919.15M ▼ |
| Q1-2025 | $500.45M ▼ | $1.31B ▼ | $371.29M ▼ | $933.95M ▼ |
| Q4-2024 | $594.35M ▲ | $1.45B ▲ | $413.82M ▲ | $1.03B ▲ |
| Q3-2024 | $427.65M | $726.5M | $201.94M | $524.56M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-162.25M ▲ | $-117.36M ▼ | $-2.55M ▲ | $251.34M ▲ | $133.3M ▲ | $-117.6M ▼ |
| Q2-2025 | $-171.9M ▲ | $-76.42M ▲ | $-5.81M ▲ | $97.66M ▲ | $24.69M ▲ | $-79.57M ▲ |
| Q1-2025 | $-202.49M ▼ | $-131.96M ▼ | $-7.27M ▼ | $40.53M ▲ | $-93.87M ▼ | $-133.79M ▼ |
| Q4-2024 | $-178.91M ▼ | $-115.43M ▼ | $275.46M ▲ | $10.64M ▼ | $167.19M ▲ | $-117.08M ▼ |
| Q3-2024 | $-95.84M | $-59.23M | $-4.56M | $16.46M | $-46.92M | $-63.79M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License and Service | $20.00M ▲ | $10.00M ▼ | $20.00M ▲ | $0 ▼ |
CEO
Christopher C. Gibson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 151
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:39.78M
Value:$192.93M
ARK INVESTMENT MANAGEMENT LLC
Shares:33.55M
Value:$162.7M
BLACKROCK, INC.
Shares:31.74M
Value:$153.94M
Summary
Showing Top 3 of 348